What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His main research concerns Pharmacogenetics, Pharmacology, Internal medicine, Genotype and Genetics. His Pharmacogenetics research incorporates themes from Thiopurine methyltransferase, Pharmacogenomics, Bioinformatics and Drug. The study incorporates disciplines such as SNP, Paclitaxel and Toxicity in addition to Pharmacology.
His research in Internal medicine intersects with topics in Gastroenterology, Surgery, Oncology and Therapeutic index. His research investigates the link between Genotype and topics such as Irinotecan that cross with problems in Odds ratio. While the research belongs to areas of Genetics, Howard L. McLeod spends his time largely on the problem of Molecular biology, intersecting his research to questions surrounding Point mutation, Exon, Dihydropyrimidine dehydrogenase deficiency, DPYD and Dihydropyrimidine dehydrogenase.
His most cited work include:
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects (1437 citations)
- Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. (1222 citations)
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin (659 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Pharmacogenetics, Oncology, Pharmacology and Genetics. His Internal medicine study typically links adjacent topics like Genotype. The Pharmacogenetics study combines topics in areas such as Pharmacogenomics, Bioinformatics, Intensive care medicine, Dosing and Single-nucleotide polymorphism.
His study explores the link between Oncology and topics such as Breast cancer that cross with problems in CYP2D6. The concepts of his Pharmacology study are interwoven with issues in Paclitaxel and Toxicity. His research combines Molecular biology and Genetics.
He most often published in these fields:
- Internal medicine (38.30%)
- Pharmacogenetics (30.30%)
- Oncology (26.22%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (38.30%)
- Oncology (26.22%)
- Cancer (17.27%)
In recent papers he was focusing on the following fields of study:
Howard L. McLeod spends much of his time researching Internal medicine, Oncology, Cancer, Pharmacogenetics and Cancer research. His Internal medicine study frequently involves adjacent topics like Pharmacology. The Pharmacology study which covers Tamoxifen that intersects with CYP2C9.
His work deals with themes such as Breast cancer, FOLFOX, Toxicity, Bevacizumab and Colorectal cancer, which intersect with Oncology. His work carried out in the field of Cancer brings together such families of science as Precision medicine, Pharmacogenomics, Gene mutation, Biomarker and Cohort. His studies deal with areas such as Anesthesia, CYP2C19, Genome-wide association study, Single-nucleotide polymorphism and Bioinformatics as well as Pharmacogenetics.
Between 2015 and 2021, his most popular works were:
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (157 citations)
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. (127 citations)
- Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study (127 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Howard L. McLeod focuses on Internal medicine, Pharmacogenetics, Cancer, Oncology and Pharmacology. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology. The various areas that he examines in his Pharmacogenetics study include Genetic testing, Drug, Single-nucleotide polymorphism and Bioinformatics.
His Oncology research integrates issues from Clinical pharmacology, Mutation, Guideline, Receptor and Metastatic basal cell carcinoma. His biological study spans a wide range of topics, including CYP2D6, Tamoxifen and Genetic predisposition. As a part of the same scientific family, he mostly works in the field of Pharmacogenomics, focusing on Cell signaling and, on occasion, Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
